EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ALNY: Alnylam Pharmaceuticals

27 Jul 26 13:58
LAST:

282.4

CHANGE:
 10.66		OPEN:
272.0		HIGH:
284.7		ASK:
95.6		VOLUME:
699.6K
CHG(%):
3.92		PREV:
271.8		LOW:
272.0		BID:
102.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Jul 26272.0284.7272.0282.4699.6K
24 Jul 26268.7275.6265.6271.81.15M
23 Jul 26266.0269.2262.2268.71.14M
22 Jul 26270.8273.7264.2267.01.1M
21 Jul 26272.4278.3270.0271.4982.8K
20 Jul 26267.6275.3266.3272.71.36M
17 Jul 26281.0284.4266.4267.51.38M
16 Jul 26279.6286.6273.8283.21.44M
15 Jul 26281.7284.8275.8279.11.28M
14 Jul 26283.6286.8279.4281.31.09M

PROFILE

Name:Alnylam Pharmaceuticals
About:Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:675 West Kendall Street, Cambridge, MA, United States, 02142
Website:https://www.alnylam.com
CUSIP:02043Q107
CIK:0001178670
ISIN:US02043Q1076
FIGI:BBG000BFGNJ5
LEI:529900S3ZI14OWRJII50

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:78.65 
Forward P/E:23.22 
PEG Ratio:4.88 
Price to Sales:18.77 
Price to Book:38.84 
Profit Margin:0.01 
Operating Margin:0.29 
Return on Assets:0.04 
Return on Equity:0.33 
EPS Ratio:3.98 
Revenue:3.21B 
EBITDA:321.02M 
Shares:133.51M 
Market Cap:37.708B 

TECHNICAL INDICATORS

MA5:272.223.7%
MA10:274.482.9%
MA20:290.582.9%
MA50:291.703.3%
MA100:302.967.3%
MA200:353.5425.2%
STO9:77.77
STO14:13.49 
RSI14:28.64 
WPR14:-73.01
MTM14:-41.26
ROC14:-0.13 
ATR:16.47 
Week High:284.680.8%
Week Low:262.217.7%
Month High:380.0034.5%
Month Low:262.2125.2%
Year High:495.5575.5%
Year Low:262.217.7%
Volatility:20.49